Regentis Biomaterials (RGNT) Cash & Equivalents (2024 - 2025)
Regentis Biomaterials (RGNT) reported Cash & Equivalents of $7.4 million for Q4 2025, up 3121.83% year-over-year from $229000.0 in Q4 2024, and up 3121.83% quarter-over-quarter from $229000.0 in Q4 2024.
Regentis Biomaterials (RGNT) Cash & Equivalents (2024 - 2025) Analysis & Trends
Regentis Biomaterials (RGNT) has 2 years of Cash & Equivalents data on file, last reported at $7.4 million in Q4 2025.
- Cash & Equivalents for Q4 2025 came in at $7.4 million, up 3121.83% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.4 million (up 3121.83% YoY), and the FY2025 annual result was $7.4 million, up 3121.83% from the prior year.
- Cash & Equivalents improved to $7.4 million in Q4 2025 per RGNT's latest filing, from $229000.0 in the prior quarter.
- Over five years, Cash & Equivalents peaked at $7.4 million in Q4 2025 and troughed at $229000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 2.01 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 813.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 2.24 Bn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 1.66 Bn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 521.40 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 561.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 138.80 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 1.06 Bn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 2.02 Bn |
| 10 | Regentis Biomaterials | 3.72 Mn | -3.66 Mn | - | 7.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.38 Mn |
| Dec 31, 2024 | 229,000.00 |